Across TCGA pan-cancer cohorts, SNORD116-17 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated SNORD116-17 data layer compared with 9 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher SNORD116-17 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SNORD116-17 expression acts as an unfavorable survival marker.

OV and LUSC are the cancer types where SNORD116-17 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Median	II,III,IV	0.028	0.844	<.001	48	view →
LUSC	OS	Median	All	0.078	0.776	<.001	12	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: SNORD116-17 tumor-vs-normal RNA expression · all SNORD116-17 data types